原发于女性生殖系统非霍奇金淋巴瘤的诊断及治疗进展

Progress on diagnosis and treatment of primary non- Hodgkin lymphoma in the female genital tract

  • 摘要: 原发于女性生殖系统淋巴瘤(primary lymphoma of female genital tract,PLFGT)发病较为罕见,病因尚未明确。患者临床表现不典型,可无症状,因无意发现盆腔肿块就诊,或表现为非特异性症状,如腹部不适、腹痛、腹胀、阴道出血或排液等,可伴有B症状。结合影像学特征可提示PLFGT可能。病理形态学为确诊该病的关键,还需借助免疫组织化学和流式细胞术等来进一步明确诊断及分型。PLFGT以非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)最为常见,除需与继发性生殖道淋巴瘤相鉴别外,还要与原发于女性生殖系统的其他恶性肿瘤相鉴别。目前治疗尚无统一标准,借鉴NHL的治疗原则,对于PLFGT患者,建议选择个体化的治疗方案。R-CHOP方案的应用明显提高了B细胞NHL患者的生存率。但化疗作为PLFGT的首选及标准治疗的有效性和安全性仍需进一步研究,并按照淋巴瘤国际预后指数(international prognostic index,IPI)进行预后评价。

     

    Abstract: Primary lymphoma of female genital tract (PLFGT) is uncommon, and its etiology is unclear. It can present with pain, distention, vaginal bleeding, or discharge or be found as an incidental finding at a routine pelvic examination or surgery for other indications. PLFGT can be diagnosed with imaging, with pathomorphology being the key to diagnosing this disease. Further diagnosis and typing are needed with flow cytometry and immunohistochemistry. PLFGT should be differentiated from secondary genital lymphoma and other primary malignant tumors of the reproductive system. Preoperative diagnosis can be challenging due to its rarity. In addition, there is a lack of experience in treating PLFGT. Based on the pathological classification, staging, and non-Hodgkin lymphoma (NHL) guidelines, an individualized approach should be determined. R-CHOP has been found to significantly improve the survival of patients with NHL. However, the efficacy and safety of chemotherapy as the standard treatment for PLFGT still needs to be confirmed. Prognosis was evaluated according to the international prognostic index (IPI).

     

/

返回文章
返回